ALT is approach a readout from IMPACT, a phase 2b study of pemvidutide in MASH. MDGL's results with its launch of MASH drug Rezdiffra demonstrate the multi-billion-dollar potential of a MASH drug, ...
Altimmune (NASDAQ:ALT) lost ~64% in the premarket on Thursday after the company announced a mixed readout from a mid-stage trial for pemvidutide, its experimental therapy for a liver condition known ...
In my last note on Altimmune, Inc. (ALT) shared in late August, I made the bull case for its stock. I discussed the Gaithersburg, Maryland based biotech's lead and only drug candidate, pemvidutide, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback